Autori: Andric Zoran G
| Naslov | HERIZON: A phase II study of HER-Vaxx (IMU-131), a HER2targeting peptide vaccine plus standard of care chemotherapy in patients with HER2+advanced stomach cancer - Dose-dependent anti-cancer antibodies correlating with improved clinical outcome (Meeting Abstract) |
| Autori | Tobias Joshua Kundi Michael Garner-Spitzer E Zielinski Christoph Maglakelidze Marina Andric Zoran G Petrovic Z Nagarkar R Chawla T Chong LO Nixon B Yavrom S Ede NJ Wiedermann Ursula |
| Info | ANNALS OF ONCOLOGY, (2023), vol. 34 br. , Suppl. 2, str. S864-S864 |
| Ispravka | ISI/Web of Science Članak Elečas Rang časopisa |
| Naslov | Impact of TTFields therapy on global and functional health-related quality of life (HRQoL) in metastatic non-small cell lung cancer (mNSCLC) from the pivotal LUNAR study (Meeting Abstract) |
| Autori | Kotecha R ... Andric Zoran G ... (broj koautora 20) |
| Info | ANNALS OF ONCOLOGY, (2023), vol. 34 br. , Suppl. 2, str. - |
| Projekat | Novocure |
| Ispravka | ISI/Web of Science Članak Elečas Rang časopisa |
| Naslov | Tumor Treating Fields therapy with standard systemic therapy versus standard systemic therapy alone in metastatic non-small-cell lung cancer following progression on or after platinum-based therapy (LUNAR): a randomised, open-label, pivotal phase 3 study (Article) |
| Autori | Leal Ticiana A ... Andric Zoran G ... (broj koautora 25) |
| Info | LANCET ONCOLOGY, (2023), vol. 24 br. 9, str. 1002-1017 |
| Projekat | Novocure |
| Ispravka | ISI/Web of Science Elečas Rang časopisa Citati: ISI/Web of Science |
| Naslov | Tumor Treating Field (TTFields) therapy with standard of care (SOC) in metastatic non-small cell lung cancer (mNSCLC) following platinum failure: Randomized, phase 3 LUNAR study (Meeting Abstract) |
| Autori | Leal Ticiana A ... Andric Zoran G ... (broj koautora 20) |
| Info | JOURNAL OF CLINICAL ONCOLOGY, (2023), vol. 41 br. 17, Suppl. S, str. - |
| Projekat | Novocure |
| Ispravka | ISI/Web of Science Elečas Rang časopisa |
| Naslov | HERIZON: A phase 2 study of HER-Vaxx (IMU-131), a HER2t-argeting peptide vaccine plus SOC chemotherapy in patients with HER2+advanced stomach cancer - correlation of the antibody responses and clinical outcome (Meeting Abstract) |
| Autori | Tobias Joshua Kundi Michael Garner-Spitzer E Zielinski Christoph Maglakelidze Marina Andric Zoran G Petrovic Zeljko M Nagarkar R Chawla T Chong LMO Nixon B Yavrom S Ede NJ Wiedermann Ursula |
| Info | ANNALS OF ONCOLOGY, (2023), vol. 34 br. , Suppl. 1, str. S4-S4 |
| Ispravka | ISI/Web of Science Članak Elečas Rang časopisa |
| Naslov | RESILIENT part 2: A randomized, open-label phase III study of liposomal irinotecan versus topotecan in adults with relapsed small cell lung cancer (SCLC) (Meeting Abstract) |
| Autori | Rudin CM Dowlati A Chen Y Navarro Mendivil AF Yang JC-H Stojanovic Goran Rich P Andric Zoran G Wu Y-L Chen H Zhang L Yeung S Benzaghou FM Paz-Ares L Bunn PA |
| Info | JOURNAL OF THORACIC ONCOLOGY, (2023), vol. 18 br. 4, Suppl. S, str. S129-S130 |
| Projekat | Ipsen |
| Ispravka | ISI/Web of Science Elečas Rang časopisa |
| Naslov | HERIZON overall survival results: A study of IMU-131, a HER2 targeting peptide vaccine, plus standard of care chemotherapy in patients with HER2 overexpressing metastatic or advanced gastric/GEJ cancer (Meeting Abstract) |
| Autori | Maglakelidze Marina Ryspayeva D Andric Zoran G Petrovic Zeljko M Bulat IV Nikolic Ivan V Chawla T Nagarkar R Wiedermann Ursula Blumenstein BA Chong LMO Ede NJ Nixon B Good AJ |
| Info | ANNALS OF ONCOLOGY, (2022), vol. 38 br. 9, Suppl. 9, str. S1460-S1460 |
| Projekat | Imugene Limited |
| Ispravka | ISI/Web of Science Članak Elečas Rang časopisa |
| Naslov | Randomized phase III study comparing the efficacy and safety of CT-P16, a new biosimilar, to reference bevacizumab (Avastin (R)) in patients with metastatic or recurrent non-small cell lung cancer (NSCLC) (Meeting Abstract) |
| Autori | Ohe Yuichiro ... Andric Zoran G ... (broj koautora 17) |
| Info | CANCER RESEARCH, (2022), vol. 82 br. 12, Suppl. S, str. - |
| Ispravka | ISI/Web of Science Elečas Rang časopisa |
| Naslov | Clinical potential of circulating tumor DNA (ctDNA)-based molecular response (MR) and baseline blood-based tumor mutational burden (bTMB) for monitoring response to firstline (1L) chemoimmunotherapy in advanced squamous non-small cell lung cancer (sqNSCLC) (Meeting Abstract) |
| Autori | Ciardiello F Feng Z Smith NR Andric Zoran G Shell S Yablonovitch A Guezel G Scheuenpflug J |
| Info | ANNALS OF ONCOLOGY, (2022), vol. 33 br. 7, Suppl. 7, str. S1050-S1051 |
| Projekat | Merck |
| Ispravka | ISI/Web of Science Članak Elečas Rang časopisa Citati: ISI/Web of Science |
| Naslov | 1-year follow-up of a phase III study to compare efficacy and safety of a bevacizumab biosimilar, CT-P16, and reference bevacizumab as first-line treatment for metastatic or recurrent non-squamous non-small cell lung cancer (Meeting Abstract) |
| Autori | Verschraegen Claire Andric Zoran G ... (broj koautora 20) |
| Info | ANNALS OF ONCOLOGY, (2022), vol. 33 br. 7, Suppl. 7, str. S1024-S1025 |
| Projekat | Celltrion Inc. |
| Ispravka | ISI/Web of Science Članak Elečas Rang časopisa Citati: ISI/Web of Science |
